Articles published by BeiGene, Ltd.
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
November 09, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene to Present at the Jefferies London Healthcare Conference
November 08, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
October 20, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
September 19, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
September 19, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
August 02, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Reports Third Quarter 2022 Financial Results
November 09, 2022
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Reports Second Quarter 2022 Financial Results
August 04, 2022
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
May 17, 2022
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Reports First Quarter 2022 Financial Results
May 05, 2022
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
February 25, 2022
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Reports Third Quarter 2021 Financial Results
November 04, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Announces Inclusion in FTSE Russell Indices
September 20, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
September 15, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.